The tweet was deleted by the author.
But we saved everything 🙂.
Camp4 Therapeutics Corp announced it will present new preclinical data at the TIDESUSA conference in Boston.
The company plans to showcase results demonstrating its lead candidate's ability to improve seizure threshold and severity in a SYNGAP1 disease model. The announcement is aimed at the scientific and medical communities, highlighting key advancements in early-stage research with potential implications for neurological disorders. Further details are available in the company's official press release.
Camp4 Therapeutics has previously detailed a new regRNA catalog powered by Capture-seq technology for gene expression in a preprint release. The company also hosted a ski outing last month to support team bonding and recognize employee contributions, according to a company announcement. These developments follow the ongoing expansion of Camp4’s scientific and organizational initiatives.